Dr. Parameswaran received her doctoral degree from the Tamilnadu Dr. MGR University in Biomedical Sciences. She completed her postdoctoral training at the University ofNebraska Medical Center, NE, USA where she pursued her research utilizing induced pluripotent stem cells to generate retinal cells and understanding the mechanism involved in retinal development and regeneration. She joined RadheshyamKanoi Stem Cell Laboratory as Assistant Professor during March 2014 with anaim to establish a self-sufficient research laboratory capable of generating patient-specific induced pluripotent stem cells for therapy and disease modeling in ocular diseases.
Current Research focuses on generating human induced pluripotent stem cells(iPSCs) from various ocular degenerative diseases and utilizing them for studying ocular development and (iPS) diseases.
Patient derived induced pluripotent stem cells (iPSCs) for modeling retinoblastoma tumorigenesis
Retinoblastoma (RB) is a common pediatric intraocular tumor. Currently, there are no adequate models available to provide an insight into the mechanism of RB tumorigenesis. The project aims to test the feasibility of generating induced pluripotent stem cells (iPSCs) from germline RB patients. It is hypothesized that the RB patient derived-induced pluripotent stem cells (RB‐iPSCs) when differentiated towards retinal lineage might recapitulate RB1-directed tumorigenesis. Towards generating RB-iPSCs, orbital adipose tissues from retinoblastoma patients post-enucleation was obtained. Orbital adipose mesenchymal stem cells (OA-MSCs) were isolated and characterized by the expression of surface marker CD105. These OA-MSCs were reprogrammed by nucleofection of episomal plasmids carrying pluripotency factors to generate RB-iPSCs. These RB-iPSCs express the pluripotency markers and has the potential to differentiate into all the three lineages (ectoderm, endoderm and mesoderm). The results provide evidence for the feasibility of iPSC generation from germline RB1 patient. The differentiation of RB-iPSCs to retinal lineage is currently being carried out.
Generation of retinal pigment epithelial cells from induced pluripotent stem cells
The utility of pluripotent stem cells in cell therapy was shown by a recent clinical trial conducted by Advanced cell technology to treat Age-related macular degeneration (AMD) and Stargardt disease (SD). The clinical trials suggested that the human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells were safe and well-tolerated by both AMD and SD patients. One of the two important factors associated with the adverse effect seen in the clinical trial was the use of immunosuppressive regimen followed owing to the allogeneic nature of the source cells. Induced pluripotent stem cells (iPSCs) have been identified as an autologous and ethical source of stem cells with potentials similar to human embryonic stem cells. In this project, induced pluripotent stem cells were generated from skin fibroblasts of normal individuals after obtaining informed consent. The induced pluripotent stem cells was differentiated into retinal pigment epithelial cells by following a stepwise protocol which recapitulates normal retinal and RPEhistogenesis.
2016 - 2019
Early Career Research Award – SERB
2003 - 2008
Reseach Fellowship –CSIR
Ms Ambily Vincent
Ms Ambily Vincent
Vision Research Foundation
No. 41 (old 18), College Road,
Chennai - 600 006, Tamil Nadu , India.
Ph No: +91-44-42271500,